f.haddad
TL2 Moderator · Groningen
Contributes reviews on supplier material. Based in Groningen.
Joined 27 March 2025 · last posted 3d
109Posts here
4Topics
1Solutions
1.2kLikes received
501Likes given
25Badges
204Days visited
3.9kPosts read
Recent activity
Full stream-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #107 · Access › International · 25 Jul 2026 · 13 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Follow-up: Signs of dehydration worth acting on Replied, post #26 · Safety › Adverse events · 15 Jul 2026 · 2 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #23 · Sourcing › Regulatory · 15 Jul 2026 · 0 likes Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #59 · Practice › Dosing & titration · 12 Jul 2026 · 18 likes Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #118 · Evidence › Journal club · 12 Jul 2026 · 0 likes SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological endpoint. Notable because soft endpoints are avoided. Two…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #52 · Compounds › Retatrutide · 10 Jul 2026 · 9 likes post #51 answers the question as asked. The question underneath it is different. Thank you for the correction. I have edited my earlier post with a note rather than…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #57 · Analytics › Impurities & related substances · 8 Jul 2026 · 0 likes post #56 answers the question as asked. The question underneath it is different. Acetate content: counter-ion content. Trifluoroacetate or acetate from the salt form of…
-
Submitting a sample: the process end to end Replied, post #57 · Sourcing › Independent verification · 4 Jul 2026 · 0 likes I read post #55 twice before replying, because I had assumed the opposite. Having read the exchange above, I think I was wrong earlier in this topic and I want to say…
-
Tracking a shortage from primary sources rather than rumour Replied, post #71 · Access › Shortages · 26 Jun 2026 · 8 likes Patient advocacy during shortages: some advocacy groups advocate for patients during shortages. Knowing who they are and following their communication is useful.
-
NHS criteria and how they are applied in practice Replied, post #7 · Regional › UK & Ireland · 20 Jun 2026 · 8 likes Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with…
-
What steady state means for the decision to escalate Replied, post #14 · Practice › Dosing & titration · 15 Jun 2026 · 23 likes Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a…
-
Racemisation and why it is invisible to a mass measurement Replied, post #122 · Analytics › Impurities & related substances · 15 Jun 2026 · 2 likes Dimer and higher-order multimers: two or more peptide molecules bonded together. They appear at double the mass and higher. They may or may not separate from the…